Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Clinical trial NCT07252479 · RECRUITING

Trial details

NCT number: NCT07252479
Sponsor: Adlai Nortye Biopharma Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors (Phase 1)RAS Mutation

Start date: 2026-01-28
Primary completion: 2028-01-31
Enrollment: 118

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.